anti-COVID-19 spike protein VNARs (Elasmogen/University of Minnesota)

N/A

Report date: 2025/03/14 16:55:21

Base Information

Drug Nameanti-COVID-19 spike protein VNARs (Elasmogen/University of Minnesota)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of MinnesotaElasmogen Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A